What’s the difference between IBS and IBD? IBS is a disorder of the gastrointestinal (GI) tract. IBD is inflammation or destruction of the bowel wall, which can lead to sores and narrowing of the intestines. Abstract: An association between hematological cancers and inflammatory bowel disease (IBD) has previously been suggested, but the risk of IBD […]
Polycythemia Vera patient advocate on living with MPN, Diane’s story
September Blood Cancer Awareness Month Spotlight by David Wallace David Wallace, your host with PV Reporter, talks to fellow PV patient advocate Diane Rose about living with Polycythemia Vera. Diane shares her patient story as we talk about how she was diagnosed, treatment, ET shifting to PV, being your own advocate, fear of needles and […]
Differential cytokine network profile in Polycythemia Vera and Secondary Polycythemia
Authors: Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Maria Gabriela Berzoti-Coelho, Raquel Tognon, Natalia de Souza Nunes, Belinda Simões, Ítalo Sousa Pereira, Daniela Carlos, Lucia Helena Faccioli, Lorena Lobo de Figueiredo-Pontes, Fabiani Gai Frantz & Fabíola Attié de Castro Scientific Reports volume 10, Article number: 7032 (2020) Abstract Polycythemia vera (PV) is a clonal disorder resulting from neoplastic transformation of hematopoietic stem cells, while secondary polycythemia (SP) is a disease characterized by increased absolute […]
Immunotherapy in Myeloproliferative Diseases
by Lukas M. Braun 1,2 and Robert Zeiser 1,3,4,5,* 1 Department of Medicine I, Medical Center—University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany; lukas.braun@uniklinik-freiburg.de 2 Faculty of Biology, University of Freiburg, 79104 Freiburg, Germany 3 German Cancer Consortium (DKTK) Partner Site Freiburg, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 4 […]
PTG-300 Hepcidin Mimetic Receives FDA Orphan Drug Designation for Treatment of Polycythemia Vera
NEWARK, Calif., June 17, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide mimetic of the natural hormone hepcidin currently in clinical development for the treatment of polycythemia vera and hereditary hemochromatosis. “Receiving […]
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 35
- Next Page »
